Results 201 to 210 of about 5,026,728 (347)
Objective This study aimed to identify in patients with systemic lupus erythematosus (SLE) with clinically active disease the attainment of frequency and determinants of Lupus Low Disease Activity State (LLDAS) and Definition of Remission in SLE (DORIS) and the frequency and determinants of flare and damage accrual after target attainment.
Yanjie Hao +39 more
wiley +1 more source
Family Physicians' Decision-making in Mechanical Ventilation Withdrawal: A Cross-sectional Study. [PDF]
Pankaew T, Kanhasing R, Wongpradit W.
europepmc +1 more source
Objectives There is growing interest in evaluating new strategies to delay or prevent post‐traumatic osteoarthritis (PTOA) in individuals who have sustained anterior cruciate ligament (ACL) injury. This study sought to determine characteristics of potential treatments that are acceptable to patients with ACL injury.
Kevin Kennedy +9 more
wiley +1 more source
Re: The Gender Wage Gap Among Early-Career Family Physicians. [PDF]
Reavis K, Harris D, Watson BN.
europepmc +1 more source
Objective The objective was to identify factors determining acute arthritis resolution and safety with colchicine and prednisone in acute calcium pyrophosphate (CPP) crystal arthritis. Methods We conducted a post hoc analysis of the COLCHICORT trial, which compared colchicine and prednisone for the treatment of acute CPP crystal arthritis, using a ...
Tristan Pascart +14 more
wiley +1 more source
Insights into diabetes remission services: perspectives from general practitioners, family physicians and multidisciplinary teams. [PDF]
Mongkolsucharitkul P +12 more
europepmc +1 more source
The Role of the Family Physician In the Care of the Child With Cancer
Donald J. Fernbach
openalex +1 more source
Objective To evaluate the efficacy and safety of baricitinib in pediatric patients with active juvenile idiopathic arthritis–associated uveitis (JIA‐U) or chronic anterior antinuclear antibody–positive uveitis, who had an inadequate response to methotrexate (MTX) or biologic disease‐modifying antirheumatic drugs (bDMARDs).
Athimalaipet V. Ramanan +7 more
wiley +1 more source

